Zacks Investment Research on MSN
Will AbbVie's neuroscience franchise aid top-line growth in Q1?
AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...
2d
Teams led by CSIR women scientists report advances in research on depression mechanisms in females
CSIR women scientists in Hyderabad advance research on female depression mechanisms and sustainable biofuels, highlighting ...
How does the amygdala influence drinking? New research shows sex-specific neural pathways: amygdala reactivity leads to ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer ...
Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results